@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAbIrtA-l_-3yG43Y1EyZwnAPgT8A2Yk9kvgNNE63Y7e8> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAbIrtA-l_-3yG43Y1EyZwnAPgT8A2Yk9kvgNNE63Y7e8#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix schem: <http://resource.belframework.org/belframework/1.0/namespace/selventa-legacy-chemical-names/> .
@prefix sdis: <http://resource.belframework.org/belframework/1.0/namespace/selventa-legacy-diseases/> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix mesh: <http://purl.bioontology.org/ontology/MSH/> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   sub:_1 occursIn: mesh:D017667 , species:9606 ;
    rdf:object sdis:adipocyte%20lipolysis ;
    rdf:predicate belv:decreases ;
    rdf:subject schem:serum%20insulin ;
    a rdf:Statement .
  sub:assertion rdfs:label "a(SCHEM:\"serum insulin\") -| path(SDIS:\"adipocyte lipolysis\")" .
}
sub:provenance {
   beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_3 ;
    pav:version "1.4" .
  sub:_2 prov:value "Furthermore, studies of patients with insulin-secreting tumors suggest that inhibition of hepatic glucose production is the major mechanism whereby insulin lowers plasma glucose in the fasting state. Insulin first acts directly upon adipose tissue to suppress lipolysis and decrease levels of circulating free fatty acids. This, in turn, may cause the inhibition of hepatic glucose production" ;
    prov:wasQuotedFrom pubmed:10199397 .
  sub:_3 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:10199397 ;
    prov:wasDerivedFrom beldoc: , sub:_2 .
}
sub:pubinfo {
   this: dct:created "2014-07-03T14:29:46.738+02:00"^^xsd:dateTime ;
    pav:createdBy orcid:0000-0001-6818-334X , orcid:0000-0002-1267-0234 .
}